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Summary Treatment of metastatic renal cell carcinoma
(mRCC) has evolved rapidly over the last two decades as major
pathways involved in pathogenesis have been elucidated.
These include the vascular endothelial growth factor (VEGF)
axis and mammalian target of rapamycin (mTOR). Therapies
targeting the VEGF pathway include bevacizumab, sorafenib,
sunitinib, pazopanib, and axitinib, whereas temsirolimus and
everolimus inhibit the mTOR pathway. All of these novel
therapies—VEGF and mTOR inhibitors—are associated with
a variety of unique toxicities, some of which may necessitate
expert medical management, treatment interruption, or dose
reduction. Common adverse events with newer drugs include
hypertension, skin reactions, gastrointestinal disturbances, thy-
roid dysfunction, and fatigue. Skilled management of these
toxicities is vital to ensure optimal therapeutic dosing and
maximize patient outcomes, including improved survival and
quality of life. This review describes and compares the toxicity
profiles of novel molecularly targeted agents used in the treat-
ment of mRCC and presents guidance on how best to prevent
and manage treatment-related toxicities. Particular attention is
given to axitinib, the newest agent to enter the armamentarium.
Axitinib is a second-generation receptor tyrosine kinase inhib-
itor with potent VEGF receptor inhibition that provides durable
responses and superior progression-free survival in advanced
RCC compared with sorafenib.
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Introduction
The incidence of kidney cancer has been increasing world-
wide, accounting for approximately 2% of all cancers (ex-
cluding non-melanoma skin cancer) [1]. In 2010, 287,421
new cases and 122,302 deaths were estimated and, by 2015,
325,433 new cases and 138,629 deaths are expected to
occur [2]. Incidence and mortality rates were highest for
men in more developed areas, where kidney cancer com-
prised 4% of all cancers [3]. Although 5-year survival rates
approximate 85% for patients with localized renal cell car-
cinoma (RCC) (the most common type of kidney cancer),
patients with advanced disease have a 5-year survival rate of
only 10% [4]. Nearly half of patients with RCC eventually
develop advanced disease including 30% of patients initially
presenting with advanced disease and another 20–30% with
early-stage disease who relapse after nephrectomy [4]. Kid-
ney cancer subtypes include clear cell RCC (85%) and the
less common non-clear cell cancers, including papillary,
collecting duct, and chromophobe RCC [5].
Chemotherapy and hormonal therapy are generally ineffec-
tive in treating kidney cancer; immunotherapy with high-dose
interleukin-2 or interferon-alfa (INF-α) is effective in some
patients, particularly those with good performance status [6].
These agents are associated with low response rates (<15%)
and significant toxicities, which often limit their use and affect
patient quality of life (QoL) [7].
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Targeted pathways in advanced RCC
Research on the molecular pathobiology of advanced RCC
has identified the vascular endothelial growth factor
(VEGF)/VEGF receptor (VEGFR) axis and the
phosphatidylinositol-3-kinase–protein kinase B/mammalian
target of rapamycin (mTOR) pathway lying downstream (the
“angiogenesis axis”) as clinically relevant targets [8–10]. Tran-
scription of vasculogenic mediators including VEGF and
platelet-derived growth factor (PDGF) is promoted by stressors
such as hypoxia, which is a strong signal for cancer angiogen-
esis. Angiogenesis in RCC is believed to be highly dependent
on VEGF, due mainly to the high frequency of germline
mutations in the von Hippel-Lindau (VHL) tumor suppressor
gene. VHL mutations result in constitutive stabilization of the
transcription factors HIF-1α and HIF-2α, which activate
VEGF genes, thereby promoting angiogenesis [11]. Approxi-
mately 40% to 60% of patients with VHL disease, an autoso-
mal dominant familial cancer disorder, develop clear cell RCC
[11–13]. VHL mutation is also associated with approximately
50% of nonhereditary (sporadic) clear cell RCC.
The VEGF/VEGFR axis plays a critical role in tumor
growth and survival [9]. Inhibitors of this pathway are
thought to exert their effects by inducing apoptosis,
cytostasis, and restrictive effects on tumor vasculature
[10]. VEGF-targeted agents include the monoclonal an-
tibody bevacizumab which neutralizes VEGF itself, and
receptor tyrosine kinase inhibitors (TKIs) such as sora-
fenib, sunitinib, pazopanib, and axitinib. These agents
target the VEGFRs, as do additional TKIs in ongoing
clinical development, with effects that extend beyond
the VEGFRs [14, 15].
The new wave of US Food and Drug Administration–
approved molecularly targeted antiangiogenic agents has
largely supplanted cytokines as first- and second-line therapy
for metastatic RCC (mRCC). Second-generation molecularly
targeted therapies in development include axitinib (a selective
and highly potent VEGFR inhibitor); tivozanib and cediranib
(also VEGFR inhibitors); brivanib (inhibitor of VEGFR and
fibroblast growth factor receptor); motesanib (inhibitor of
VEGFR, PDGF receptor, and c-Kit); XL184 (inhibitor of
VEGFR-2, MET, and RET); and VEGF TRAP (novel inhib-
itor of VEGF-A).
Timely and appropriate management of treatment-
related toxicities is vital in order to deliver therapy
safely and optimally. This review describes and com-
pares the toxicity profiles of antiangiogenic agents used
in mRCC. Particular attention is devoted to axitinib, an
antiangiogenic multi-targeted TKI in active clinical de-
velopment for mRCC. Guidelines for preventing and
managing treatment-related toxicities of axitinib are pre-
sented, which also have general relevance to all of the
small-molecule angiogenesis inhibitors.
Efficacy of new antiangiogenic agents in pivotal clinical
trials
Findings from key clinical trials of approved antiangiogenic
agents (sorafenib, sunitinib, bevacizumab, and pazopanib)
in advanced RCC have reported consistent prolongation of
progression-free survival (PFS) and, in some cases, overall
survival (OS) in both treatment-naïve and previously treated
patients (Table 1).
The newer agent, axitinib, is a potent, selective, second-
generation inhibitor of VEGFR-1, 2, and 3 with clinical
antitumor activity in a variety of solid tumors [16–20]. In
a recent pivotal randomized phase III trial, axitinib demon-
strated statistically superior PFS compared with sorafenib,
as well as a higher response rate [21]. Although many of the
toxicities of axitinib are shared with those of the other TKIs,
there are important differences, most notably an apparent
higher incidence of hypertension. Moreover, the safety
profile for axitinib is distinct from that of sorafenib.
Common adverse events (AEs) more frequent with sora-
fenib versus axitinib were hand-foot syndrome (HFS),
rash, alopecia, anemia, hypophosphatemia, hypocalcemia,
and elevated lipase whereas the predominant toxicities with
axitinib were hypertension, fatigue, nausea, vomiting, and
hypothyroidism [21].
Axitinib first demonstrated clinical activity in patients with
refractory advanced RCC in a phase II study [18], in which 52
patients with cytokine-refractory mRCC and clear-cell histol-
ogy received axitinib 5 mg twice daily (BID). An overall
response rate of 44% was reported with a median duration
of response of 23.0 months (range, 4.2–29.8 months). Median
time to progression was 15.7months (range, 8.4–23.4months)
and median OSwas 29.9 months (range, 2.4–35.8 months). In
a second phase II trial [19], patients with sorafenib-refractory
mRCC received axitinib at a starting dose of 5 mg BID.
Axitinib produced a 23% response rate and median duration
of response of 17.5 months. Median PFS was 7.4 months
(95% CI, 6.7–11.0) and median OS was 13.6 months (95%
CI, 8.4–18.8).
In the recent phase III trial in patients with advanced RCC
[21], axitinib 5 mg BID demonstrated superior PFS compared
with sorafenib 400 mg BID (6.7 versus 4.7 months;
P00.0001) with a significantly higher response rate (19.4
versus 9.4%; P00.0001) (Table 1). Patient-reported QoL
was comparable between the two treatment arms.
Toxicity profile of new antiangiogenic agents for mRCC
Commonly reported toxicities for antiangiogenic agents in
patients with mRCC include class effects of fatigue, asthe-
nia, diarrhea, nausea, anorexia, rash, HFS, and hypertension
(Table 2) [21–25]. Other toxicities or combinations of side
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effects appear to be relatively specific to particular antian-
giogenic agents.
Toxicities across cancer populations
Toxicity profiles of antiangiogenic therapies lack disease
specificity and thus can be usefully summarized and
compared across disease indications. AEs reported for these
agents in patients with mRCC are very similar to toxicities
reported for sunitinib in gastrointestinal stromal tumors [22],
sorafenib in hepatocellular carcinoma [24], bevacizumab
monotherapy in glioblastoma, and bevacizumab plus che-
motherapy for metastatic colorectal cancer, non-squamous
non–small cell lung cancer, and metastatic breast cancer.
Table 1 Overview of efficacy of targeted therapies for mRCC
Bevacizumab
+ IFN-αa
Sorafenibb Sunitiniba Pazopanibb Axitiniba
Treatment-naïve
Study 1 vs IFN vs IFN vs IFN vs PBO
N0649 [23] N0189 [79] N0750 [43] N0435 [55]
PFS (mo) 11 vs 5 5.7 vs 5.6 11 vs 5 11.1 vs 2.8
HR 0 0.63; CI, 0.52–0.75;
P00.0001
HR 0 0.42; CI,
0.32–0.54;
P<0.001
HR 0 0.46; CI,
0.34–0.62; P<0.0001
ORR (CR + PR) 31 vs 6%c 5.2 vs 8.7%d 37%*
OS (mo) 23.3 vs 21.3 [78] NR 26.4 vs 21.8 [28] 32%d NR
HR 0 0.86; CI, 0.72–1.04;
P<0.1291
HR 0 0.821; CI,
0.673–1.001;
P00.051
Study 2 vs IFN OL
N0732 [80] N0155 [81]
PFS (mo) 8.5 vs 5.2 NR
ORR (CR + PR) 25.5 vs 13.1 34%
OS (mo) 18.3 vs 17.4 [25] NR
Cytokine failure
Study 1 vs PBO vs PBO OL vs PBO OL
N0116 [82] N0903 [30] N0106 [84] N0202 [55] N052 [18]
PFS (mo) 4.8 vs 2.5 5.5 vs 2.8 8.3 7.4 vs 4.2 13.7
HR 0 0.44; CI, 0.35–0.55; P<0.01
ORR (CR + PR) 10%C 10%c 44%c 29%d 44.2%c
29.9
OS (mo) NR 17.8 vs 14.3 [83] NR NR
HR 0 0.78; CI, 0.62–0.97;
P00.0287
Study 2 OL OL OL vs SOR
N0107 [85] N031 [81] N0723 [21]
PFS (mo) 8.2 NR 6.7 vs 4.7
HR 0 0.665; CI,
0.522–0.812; P00.0001
ORR (CR + PR) 20%c 37% 19.4 vs 9.4%
P00.0001
OS (mo) 19.8 NR
TKI failure
Study 1 OL N062 [19]
PFS (mo) 7.4
ORR (CR + PR) 22.6%d
OS (mo) 13.6
a Approved in the United States (Note: bevacizumab monotherapy approved only in Europe)
b Approved in the United States and Europe
c Investigator assessment
d Independent assessment
mRCC metastatic renal cell cancer, IFN-α interferon-α, PBO placebo, PFS progression-free survival, HR hazard ratio, CI 95% confidence interval,
ORR overall response rate, CR complete response, PR partial response, OS overall survival, NR not reported, OL open-label, SOR sorafenib
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VEGF inhibitors
Common AEs in patients with RCC receiving bevacizumab/
INF-α include pyrexia, anorexia, fatigue, asthenia, bleeding,
hypertension, and proteinuria [23]. Bevacizumab is also
associated with increased incidence of potentially life-
threatening gastrointestinal perforations and thrombovascu-
lar events [23, 25]. A meta-analysis of 12,294 patients with
a variety of solid tumors treated with bevacizumab in 17
randomized controlled trials reported that the addition of
bevacizumab to other cancer therapy increased the risk of
gastrointestinal perforation by 1.6- to 5.7-fold, depending
on tumor type and dose [26]. In addition, a recent meta-
analysis [27] of >10,000 patients with cancer treated with
bevacizumab revealed increased incidence of treatment-
related mortality, particularly in patients who were also
receiving taxanes or platinum agents. In phase III trials of
bevacizumab plus INF-α, congestive heart failure (CHF;
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Dose modification, % patients
Dose reduction 40 13 52 36 31
Dose interruption – 21 54 42 77
AE, % patients AE grade
All 3/4 All 3/4 All 3, 4 All 3, 4 All ≥3
Cardiovascular
Hypertension 26 3 17 4 30 12, 0 40 4, 0 40 16
Constitutional symptoms
Fatigue 33 12 37 5 54 11, 0 19 2, 0 39 11
Asthenia 32 10 – – 20 7, <1 14 3, 0 21 5
Hypothyroidism – – – – 14 2, 0 <10 <1 19 <1
Cutaneous symptoms
Rash – – 40 1 24 1, <1 – – 13 <1
Hand-foot syndrome – – 30 6 29 9, 0 <10 <1 27 5
Mucositis/stomatitis – – – – 30 1, 0 <10 <1 15 1
Gastrointestinal symptoms
Diarrhea 20 2 43 2 61 9, 0 52 3, <1 55 11
Nausea – – 23 <1 52 5, 0 26 <1, 0 32 3
Vomiting – – 16 1 31 4, 0 21 2, <1 24 3
Dyspepsia – – – – 31 2, 0 – – – –
Anorexia/decreased appetite 36 3 16 <1 34 2, 0 22 2, 0 34 5
Abdominal pain – – 11 2 11 2, 0 11 2, 0 – –
Hemorrhage/bleeding
All sites 33 3 15 2 – – 13 – – –
Laboratory
Lymphopenia – – – 13 – – 31 4, <1 33 3
Neutropenia 7 4 – – – – 34 1, <1 6 1
Thrombocytopenia 6 2 – – 68 8, 1 32 <1, <1 15 <1
Decreased phosphorus – – – 13 – – 34 4, 0 13 2
Elevated lipase – – 41 12 56 15, 3 – – 27 5
Anemia/decreased Hb 10 3 8 3 79 6, 2 – – 35 <1
Proteinuria 18 7 – – – – <10 <1 – –
mRCC metastatic renal cell cancer, VEGF vascular endothelial growth factor, TKI tyrosine kinase inhibitor, IFN-α interferon-α, Tx treatment, AE
adverse event, Hb hemoglobin
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in <1% patients) and cardiac ischemia/infarction (in 1%
of patients) were reported [23, 25].
Specific effects of TKIs commonly include hypertension,
HFS (palmoplantar erythrodysesthesia), rash, mucositis, hy-
pothyroidism, and myelosuppression (Table 2).
Across oncology trials with sunitinib, toxicities occurring
in ≥20% of patients included anemia, diarrhea, fatigue, nau-
sea, asthenia, mucositis/stomatitis, vomiting, hypertension,
HFS, and rash [28]. Sunitinib is also associated with myelo-
suppression, elevated levels of thyroid-stimulating hormone
(TSH), hypothyroidism, and hepatotoxicity including liver
failure. In addition, there is increased risk of CHF and decline
in left ventricular ejection fraction (LVEF) in 10% of patients
[29]. Prolongation of QT interval may also lead to increased
risk of ventricular arrhythmias. AEs occurring in ≥20% of
sorafenib-treated patients included rash/desquamation, diar-
rhea, fatigue, HFS, alopecia, and nausea [30]. Sorafenib is
also associated with increased risk of life-threatening bleed-
ing. A high frequency of intracerebral hemorrhage has been
reported in sorafenib- or sunitinib-treated mRCC patients with
brain metastases [31]. Pazopanib is associated with hypothy-
roidism and proteinuria, as well as having variable effects on
glucose levels [32]. Pazopanib can also cause hepatotoxicity;
monitoring of liver function is required and dose reduction
may be necessary in patients with baseline elevation in total
bilirubin and other hepatic function tests [32]. Similar associ-
ations have been observed with sorafenib, with dose reduc-
tions suggested for patients with hepatic dysfunction [33].
Hyperglycemia has been reported in 41% of pazopanib-
treated versus 33% of placebo-treated patients, whereas hypo-
glycemia was reported in 17% of pazopanib- versus 3% of
placebo-treated patients.
Toxicities of concern reported for some of the investigational
TKIs include cholecystitis and gall bladder enlargement with
motesanib, proteinuria with axitinib, and mucositis with
XL184. There appear to be some relative safety differences
across the various VEFG-inhibitor therapies, although the data
must still be considered incomplete at this time. In particular,
bevacizumab is associated with a low incidence of hypothy-
roidism, sorafenib has low cardiac toxicity compared to suniti-
nib, and recipients of pazopanib report less fatigue.
Proposed mechanisms of common toxicities
Hypertension
Hypertension occurs in 17% to 45% of TKI-treated patients
with RCC, with grade 3 or 4 hypertension reported in 3% to
16% of patients. Elevated blood pressure (BP) typically
presents early, within 3 to 4 weeks of treatment initiation
[34, 35]. Some studies of TKI-mediated BP effects reported
elevations as early as the first day [36] to first week [37] of
treatment.
The exact mechanisms underlying VEGF/VEGFR inhib-
itor–associated hypertension remain unknown but increased
BP, a dose-dependent effect of these inhibitors, is believed
to be caused by increases in vascular tone and peripheral
resistance. Interestingly, emergence of hypertension with
these agents, including axitinib, may serve as a biomarker
for antitumor efficacy [38–40].
In the sorafenib-refractory study of axitinib [19], peripheral
edema and hypertension were reported by 19.4% and 45.2%
of patients, respectively. Hypertension remains the major
cardiovascular-related toxicity of axitinib, reported in 51%
of patients [18, 19]. A pooled analysis of phase II studies of
axitinib in mRCC [40] reported that patients with at least one
diastolic BP (dBP) measurement ≥90 mmHg during treatment
had a significantly longer median OS compared with patients
with dBP <90 mmHg (30.1 versus 10.2 months, respectively;
P<0.001). Likewise, an analysis of sunitinib clinical trials in
patients with mRCC [39], showed that treatment-emergent
hypertension was an independent predictor of PFS and OS
(P<0.001). PFS was 12.5 versus 2.5 months in patients with
maximal systolic BP (sBP) ≥140 mmHg versus <140 mmHg,
respectively (P<0.001). Similarly, significant clinical benefit
was reported for dBP ≥90 mmHg compared with <90 mmHg.
Effective control of BP with antihypertensive treatment did
not affect the improved clinical outcome. Currently, a ran-
domized prospective phase II axitinib trial in patients with
mRCC is evaluating axitinib-related dBP changes as a possi-
ble predictive biomarker for response (ClinicalTrials.gov
identifier: NCT00835978).
Before starting TKI therapy, BP should be controlled for
approximately 1 week. Hypertension should be monitored
and controlled with appropriate antihypertensive agents,
with weekly monitoring of BP during the first cycle and 2
to 3 weeks thereafter until a stable BP has been reached, and
then monitored per standard medical practice [41]. Like-
wise, BP should be monitored following discontinuation of
TKI therapy since BP can drop rapidly.
Patients who develop stage I hypertension (≥140/
90 mmHg) or have increases in dBP ≥20 mmHg from base-
line should initiate antihypertensive therapy, modify the dose
of the current agent for better control, or add a second
antihypertensive agent [41]. In some instances, dose reduc-
tion of the TKI inhibitor can be implemented to manage TKI-
induced hypertension. The major classes of antihypertensive
agents, including angiotensin-converting enzyme (ACE)
inhibitors, beta blockers, and calcium channel blockers, have
been used to treat TKI-induced hypertension. There are no
consensus recommendations, however, for the use of specific
antihypertensive agents in this setting [42]. Antihypertensive
agents should be individualized to suit the patient’s clinical
status. ACE inhibitors, for example, are preferred for patients
with proteinuria, chronic kidney disease risks, or metabolic
syndrome [42].
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Cutaneous reactions
Rash, HFS, and mucositis/stomatitis are common effects of
antiangiogenic agents. HFS is characterized by palmoplantar
lesions in areas of friction or trauma, commonly in the hands
and feet. HFS may significantly affect a patient’s QoL and
physical functioning and often leads to treatment modification
or discontinuation [30, 43]. The precise mechanisms causing
these events are largely unknown. In a sunitinib study, skin
toxicity appeared after 3 to 4 weeks of treatment and was
characterized by dermal vascular modifications, scattered ker-
atinocyte necrosis, and intra-epidermal cleavage, which may
be mediated via direct anti-VEGFR and/or PDGF receptor
effects on dermal endothelial cells [44].
Hypothyroidism
Antiangiogenic agents are known to affect thyroid ho-
meostasis but the precise mechanisms are not well un-
derstood. Biochemical and clinical hypothyroidism is
commonly reported in patients with RCC receiving suni-
tinib and sorafenib [45–47]. An increase in TSH and
decreases in thyroid hormone, indicative of hypothyroid-
ism, has been reported in sunitinib-treated patients with
gastrointestinal tumors [48]. VEGFR inhibitors such as
sunitinib may induce thyroiditis and hypothyroidism via a
direct effect on the thyroid through inhibition of VEGFR
[49]. Thyroid dysfunction may also result from regression
of capillaries around thyroid follicles due to VEGFR
inhibition [50]. Changes in TSH appeared to correlate
with fatigue in patients receiving axitinib [51]. Therefore,
thyroid-function monitoring is recommended with man-
agement of hypothyroidism following standard guidelines
for levothyroxine replacement therapy [52].
Fatigue
Fatigue is experienced by 19% to 77% of patients receiving
antiangiogenic agents. The most common factors contributing
to fatigue in patients with cancer independent of treatment
with angiogenesis inhibitors are hypothyroidism, anemia, and
dehydration. Hypogonadism may also contribute to the fa-
tigue associated with sunitinib and sorafenib [53]. Fatigue has
a high impact on patient QoL and should be monitored
closely, following appropriate treatment guidelines to alle-
viate symptoms [54].
Gastrointestinal disturbance
Gastrointestinal AEs in patients with RCC treated with
antiangiogenic agents include diarrhea, nausea, and vomit-
ing (Table 3). These AEs are usually not associated with
treatment discontinuation because of successful management
by standard medical interventions such as antidiarrheal med-
ications and dietary modification.
Cardiovascular toxicities
Cardiovascular toxicities of TKIs include hypertension, pe-
ripheral edema, and cardiac dysfunction [28, 30, 55]. The rate
of TKI-associated cardiovascular toxicities is not well estab-
lished. Cardiac damage is manageable, provided the patients
receive appropriate cardiac monitoring and treatment at the
first indication of myocardial damage [56]. Monitoring for
drug-related toxicities can be challenging, as symptoms such
as dyspnea, chest, pain, and dizziness can be ambiguous dis-
ease indicators in patients with advanced cancer. The use of
beta blockers such as carvedilol and drugs such as simvastatin
has been suggested as a means to protect against TKI-induced
cardiac toxicities [56]. Importantly, decline in LVEF has pre-
ceded CHF in sorafenib- and sunitinib-treated patients, mainly
in those with a history of coronary artery disease. LVEF
declines have been observed in patients with mRCC treated
with sunitinib, but it is not known if patients with cardiac
conditions have a greater chance of developing sunitinib-
related LVEF [57]. Baseline and periodic assessment of LVEF
are strongly recommended for patients receiving TKI therapy.
Special emphasis must be placed on monitoring for the clinical
signs and symptoms of CHF. Patients with signs and symp-
toms of CHF should be thoroughly evaluated (including LVEF
assessment) and discontinue therapy. Physicians are advised to
consider carefully the cardiac risk: benefit ratio for any patient
before initiating therapy with VEGF inhibitors.
Proteinuria
Proteinuria is mostly observed in patients receiving bevaci-
zumab (Table 2). The mechanism underlying proteinuria is
unclear but it may reflect a role for VEGF in normal glo-
merular endothelial repair [58]. Patients should be moni-
tored for proteinuria before and after treatment. Therapy
should be discontinued in patients with grade 4 proteinuria.
Bleeding and wound healing
Bleeding, including epistaxis, hematemesis, gastric bleeding,
and brain hemorrhage, is associated with VEGF inhibitors
and is more common with bevacizumab [59]. While bleed-
ing is generally manageable, it can be serious and some-
times fatal. Patients with serious bleeding should not receive
bevacizumab. Angiogenesis is required for wound healing
and, thus, anti-VEGF agents may directly affect the healing
process. Wound-healing complications, such as slow or
incomplete healing following surgery, have been reported
for bevacizumab and pazopanib. These events were fatal in
some cases.
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Thromboembolic events
Angiogenesis inhibition, as well as cytotoxic chemother-
apy, is associated with increased risk of both arterial
thromboembolic events (ATE) and venous thromboem-
bolic events (VTE) [60]. Several factors related to
VEGF inhibition are believed to contribute to the in-
creased risk of ATE and VTE, including the role of
VEGF in the regeneration of endothelial cells. A pooled
analysis of clinical trials, including trials in mRCC,
reported that bevacizumab was significantly associated
with an increased risk of developing VTE in patients
with cancer [61]. In this analysis, the incidence of all-
grade and high-grade VTE was 11.9% and 6.3%, re-
spectively. A recent meta-analysis to assess the risk of
ATE reported that treatment with sunitinib and sorafenib
is associated with a three-fold increase in the risk of
ATE, with an overall incidence of 1.3% in patients with
RCC [62]. Myocardial infarction and cardiac ischemia
have also been reported for sunitinib and sorafenib.
Follow-up
Careful evaluation and follow-up of reported toxicities
and their response to management often allow patients
to continue treatment safely on the prescribed effective
doses of antiangiogenic agents. AEs leading to dose
interruption or reduction should be closely monitored
so therapy can be reinstituted once side effects improve
or resolve.
Axitinib
Axitinib-related toxicities in advanced RCC
Common toxicities
AEs associated with axitinib including a higher incidence of
hypertension compared with some of the other TKIs, gener-
ally respond to supportive measures and dose modifications.
Table 3 Toxicity profile of axitinib in phase II studies
mRCC [19] N062 mRCC [18] N052 TC [16] N060 NSCLC [20] N032 Melanoma [63] N032
Previous treatment status Sorafenib Cytokine 131 Iodine
AE, % patients AE grade
All 3/4 All 3/4 All ≥3 All 3 All >3
Fatigue 77 16 52 8 50 5 50 22 63 22
Diarrhea 61 15 60 10 48 3 41 3 31 0
Anorexia 48 0 35 2 30 0 50 0 – –
Hypertension 45 16 58 14 28 12 22 9 44 6
Nausea 44 7 44 0 33 0 34 0 22 0
Dyspnea 39 15 – – – – – – – –
Dysphonia 37 0 19 0 – – 28 0 34 0
Hand-foot syndrome 36 16 8 – 15 0 – – – 3
Mucosal inflammation 34 2 – – – – 16 0 16 0
Vomiting 32 5 21 0 13 0 19 3 – –
Weight decrease 31 5 27 0 25 3 16 0 16 0
Cough 29 0 – – – – – – – –
Headache 29 2 15 0 22 3 – – – –
Arthralgia 27 3 14 2 – – 22 0 19 6
Constipation 26 0 14 0 – – – – – –
Dysgeusia 23 0 12 0 – – – – – –
Abdominal pain 21 11 12 0 – – – – – –
Pain in extremity 21 3 19 4 – – – – 16 0
Stomatitis – – 17 2 25 0 – – 16 3
Proteinuria – – 8 0 18 5 – – 38 3
Rash – – – – 15 0 16 0 – –
mRCC metastatic renal cell cancer, TC thyroid cancer, NSCLC non–small cell lung cancer, AE adverse event
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The most common axitinib-related AEs reported across
phase II trials [16, 18–20, 63] were fatigue, diarrhea,
hypertension, and anorexia (Table 3). The most common
grade 3/4 AEs were hypertension, fatigue, and diarrhea.
The most commonly reported hematologic AE was
grade 1/2 anemia, which did not require dose reduction
or interruption [18, 20].
In the phase III study of axitinib versus sorafenib [21],
common AEs more frequently reported with sorafenib ver-
sus axitinib, respectively, included anemia (52% versus
35%), HFS (51% versus 27%), rash (32% versus 13%),
and alopecia (32% versus 4%) and AEs more frequently
occurring with axitinib versus sorafenib, respectively, in-
cluded hypertension (40% versus 29%), fatigue (39% versus
32%), nausea (32% versus 22%), vomiting (24% versus
17%), and hypothyroidism (19% versus 8%). The incidence
of diarrhea was similar for axitinib and sorafenib (55% and
53%, respectively). Axitinib does not appear to cause neu-
tropenia and thrombocytopenia, which have been reported
with sunitinib.
Axitinib toxicities are very similar and manageable in
patients with cancers other than RCC. For example, in the
phase II study of axitinib in 60 patients with advanced
thyroid cancer refractory to conventional therapy, grade ≥3
treatment-related AEs were hypertension (12%), fatigue
(5%), proteinuria (5%), and diarrhea, headache, and weight
decrease (3% each) [16].
Dose-limiting toxicities
Dose-limiting AEs leading to axitinib dose reduction or
interruption include hypertension, fatigue, and diarrhea.
In a phase I study of patients receiving 5 to 30 mg
axitinib BID [64], hypertension was the primary dose-
limiting toxicity. One patient receiving axitinib (20 mg
BID reduced to 10 mg BID) died acutely with grade 4
hemoptysis. In patients receiving the recommended phase
II 5-mg BID dose, dose-limiting toxicities were grade 2
stomatitis and grade 3 diarrhea (n01 each). In phase II
studies [18, 19], common AEs leading to axitinib dose
interruption were dyspnea, nausea, fatigue, hypertension,
and vomiting. In the sorafenib-refractory mRCC study
with axitinib [19], AEs led to study discontinuation in
19% of patients and to temporary dose interruptions or
reductions in 73% and 45% of patients, respectively. In
the cytokine-refractory mRCC study of axitinib [18], 15
patients (28.8%) had a dose reduction due to AEs. Dose
reduction was required for grade 3 diarrhea and fatigue
(n02 each); gastrointestinal upset, dehydration, myalgia,
and gout (n01 each); and grade 2 hypertension (n07). In
this latter study, some patients took axitinib continuously
for up to 5 years without evidence for cumulative
toxicities.
Management of axitinib-related toxicities in advanced RCC
Assessments and monitoring of toxicities
Pretreatment assessment should be performed with particular
attention to the presence of comorbidities (e.g., preexisting
hypertension) that may indicate more frequent monitoring and
anticipation of possible dose reductions. Patients with preex-
isting cardiovascular dysfunction and cardiac risk factors
should be monitored regularly with BP assessment at baseline
and during treatment. Thyroid profiles should be assessed at
baseline and every 2 to 3 months after initiation of therapy
[65]. Very rarely, high hematocrits have been seen with axiti-
nib [18, 66] and should be treated appropriately.
Management of common axitinib toxicities
Prevention and management strategies for axitinib-related
AEs are presented in Table 4 and discussed below.
Fatigue
Fatigue (all grades) with axitinib treatment occurs in 39% of
patients [21]. Treatment of fatigue is supportive in nature,
requiring a thorough assessment of other possible exacerbating
factors (e.g., sleep disturbance, comorbid conditions, concom-
itant medications, hypothyroidism, or anemia). Supportive
strategies include a range of approaches, from decreasing en-
ergy expenditure to psychosocial interventions. Pharmacologic
strategies include treating contributing factors (e.g., anemia,
hypothyroidism) and the judicious use of psychostimulants,
including methylphenidate and modafanil [67]. Axitinib-
induced thyroid dysfunction and hypothyroidism are easily
controlled by thyroid hormone replacement therapy [68].
Gastrointestinal symptoms
Over half of patients will experience axitinib-related gastro-
intestinal disturbances. Patients should be advised to con-
sume frequent small meals, drink clear fluids in regular
small amounts, and avoid foods or drinks that may exacer-
bate diarrhea (such as dairy products) [69–72]. Diarrhea can
be controlled with the use of standard antidiarrheal medica-
tion and proper hydration.
Hand-foot syndrome
HFS is experienced by up to 36% of axitinib-treated patients
and can be minimized by various skincare measures prior to
initiating antiangiogenic therapy [65, 73]. Although severe
episodes of HFS may necessitate dose alterations, topical
treatments and avoidance of friction, especially in the feet,
may provide some relief. In one study, patients treated with
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topical urea or tazarotene or a two-agent combination (e.g.,
urea, fluorouracil, and/or tazarotene) reported improvement
in HFS symptoms resulting from TKI therapy [74].
Hypertension
Hypertension should be controlled before starting antiangio-
genic therapy. BP ≥140/90 mmHg should be actively treated
using standard antihypertensive medications. Reaching a
target <140/90 mmHg may require different combinations
of standard agents and a different BP goal may be appro-
priate for some patients.
For hypertensive patients with uncontrolled BP, the dose of
antihypertensive medication should be increased or, if on a
maximal dose, a second agent should be added and its dose
increased as appropriate. At pretreatment assessment, hyper-
tensive patients can initiate therapy with short-acting agents to
quickly achieve BP control before exchanging medications for
longer-acting agents. This approach allows cancer therapy to
begin expeditiously. BP assessment prior to initiating therapy,
every 2 weeks during the first 3 months of therapy, and
monthly thereafter is recommended. Patients should also mon-
itor their BP daily at home (prior to taking axitinib). Axitinib-
treated patients with sBP >150 mmHg or dBP >100 mmHg or
experiencing symptoms such as headache or visual disturbance
indicating hypertension should promptly contact their physi-
cian for axitinib-dose modification.
Drug-drug interactions
Axitinib is primarily metabolized in the liver by the cyto-
chrome P450 (CYP) 3A4 isozyme and to a lesser extent by
CYP2C19 and CYP1A2. Less than 1% of the administered
dose is excreted in the urine unchanged [64]. Both inducers
and inhibitors of CYP metabolism may affect axitinib plasma
exposures. Therefore, concomitant use of known potent
Table 4 Prevention and management axitinib-related adverse events




Routine manicure/pedicure Delay or adjust dose
Remove calluses with proper tools Implement topical treatment
Cushion pressure points and protect areas
Avoid constriction/friction in concerned areas
Use moisturizer (alcohol-free) after bathing
Oral mucositis/
stomatitis [65]
Maintain oral hygiene Use mucosal-covering agents Dose reduction or interruption
Use salt and baking soda mouthwash Use topical lidocaine solutions
Consume a soft diet If oral candidiasis present:
use oral fluconazole or local
clotrimazole troche
Rash [73] Use moisturizer twice daily (alcohol-free) Topical hydrocortisone cream 1% Oral prednisone
Avoid abrasive clothing/detergents/shampoo For grade 4, provide referral
to specialistAvoid direct sunlight
Use SPF 30 lotion/clothing
Gastrointestinal
Diarrhea [69] Avoid diarrhea-enhancing foods/
drinks/supplements (e.g., lactose,
alcohol, caffeine, fiber)
Loperamide or diphenoxylate Admit patient to hospital
Drink 8–10 glasses of clear liquids daily
Nausea/Vomiting
[70–72]
Eat small meals frequently Metoclopramide, prochlorperazine,
or haloperidol; add ondansetron or
granisetron
Sip fluids steadily
Anorexia [86] Consider megestrol acetate
Constitutional
Fatigue [65, 86] Monitor fatigue levels Exclude/treat contributing conditions
(e.g., depression, hypothyroidism,
pain, anemia)
Dose reduction or interruption
Use energy-conserving strategies Provide supportive care
Use distraction strategies Consider psychostimulant (e.g.,
methylphenidate, modafanil)
SPF sun protective factor
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CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoco-
nazole, miconazole, erythromycin, telithromycin, clarithromy-
cin), as well as CYP3A4 or CYP1A2 inducers (e.g.,
carbamazepine, dexamethasone, phenobarbital, phenytoin),
should be avoided in patients receiving axitinib. Combination
therapies with agents such as 5-fluorouracil, cisplatin, carbo-
platin, docetaxel, and paclitaxel did not affect the pharmacoki-
netic profile of axitinib.
Axitinib dose modification
Dose modification or treatment interruption may be required
to alleviate axitinib-related toxicities. Stepwise increases
from the starting dose (5 mg BID) to 7 mg BID and then
10 mg BID may be instituted at 2-week intervals in the
absence of grade ≥3 AEs or the development of hyperten-
sion. The benefit of titrating to higher doses is supported by
preliminary data in RCC in which higher plasma axitinib
exposure was associated with improved outcomes [75, 76].
Dose reductions are also implemented in a stepwise fashion.
Thus, 5 mg BID is reduced to 3 mg BID, and then to 2 mg
BID, if needed. Similarly, for patients receiving 7 or 10 mg
BID, stepwise reduction should be to the next lowest dose.
Recommendations for dose modifications in patients who
develop hypertension or proteinuria are presented in Table 5.
Dose modifications for other nonhematologic and hemato-
logic events are presented in Table 6.
Conclusions
The new generation of targeted therapies for advanced RCC
offers significant benefit compared with prior approaches
such as cytokines and chemotherapy. However, significant
potential for a different spectrum of toxicities clearly exists
with these newer agents, including those targeting angiogene-
sis. Class-effects such as hypertension, fatigue, and gastroin-
testinal disturbances are common with all the antiangiogenic
agents and should be anticipated and proactively managed.
Other unique but important toxicities, including hypothyroid-
ism, proteinuria, cutaneous reactions, and hemorrhage, occur
less often. The mechanisms underlying the toxicities are begin-
ning to be revealed, but considerable research in this area is
needed. This understanding could lead to new therapies with
improved toxicity profiles and/or greater specificity for selected
subtypes of RCC.
Emerging evidence suggests that certain adverse effects
may be biomarkers for efficacy in RCC. Despite a lack of
complete understanding of the underlying biological
Table 5 Axitinib modification for hypertension and proteinuria [19]
Adverse event Action
Hypertension
sBP >150 mmHg or dBP >100 mmHg
(Two readings at least 1 h apart)
Previously normotensive: Initiate anti-HTN therapy; maintain axitinib dose
Previously HTN: Increase dose of anti-HTN therapy; if already on maximal
dose, reduce axitinib dose by one level
sBP >160 mmHg or dBP >105 mmHg
(Two readings at least 1 h apart)
Interrupt axitinib treatmenta; adjust dose of anti-HTN agents until BP
<150/100 mmHg; immediately restart axitinib treatment at one lower-dose level
Recurrent following dose reduction
(Two readings at least 1 h apart)
Reduce axitinib dose further by one level
Proteinuria
Proteinuria >1 g/24 h Perform 24-h urine collection; continue axitinib dose while awaiting test results
Proteinuria ≥2 g/24 h Interrupt axitinib treatment; wait until daily protein excretion is <2 g; restart
axitinib treatment at a same dose or reduce by one dose level
a Patients should be closely monitored for the development of hypotension
sBP systolic blood pressure, dBP diastolic blood pressure, HTN hypertensive, BP blood pressure
Table 6 Axitinib dose modification by grade of adverse eventa







3 Non-hematologic Decrease dose to one lower-dose level
Hematologic Continue same dose
4 Non-hematologic
or hematologicb
Interrupt dosing; restart at one lower-
dose level when AE improves to
CTCAE grade 2 or better
a Not including hypertension or proteinuria (see Table 3)
b Grade 4 lymphopenia or asymptomatic biochemistry abnormality
may continue without interruption
AE adverse event, CTCAE Common Terminology Criteria for Adverse
Events
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mechanisms, selected toxicities such as hypertension
may prove to be clinically useful surrogates of response
if they are reproducible and correlate well with out-
comes. Ongoing pharmacogenomic research is focused
on identifying specific gene polymorphisms that may be
associated with increased toxicity or improved outcomes
with RCC therapies.
Proper management of these AEs will ensure that
patients receive optimal benefit from these newer thera-
pies. In addition, grade 1 and 2 toxicities should not be
overlooked when treating patients since these can be
challenging for patients who must take drugs on a daily
basis, can have substantial effects on QoL and overall
healthcare costs, and may lead to treatment discontinua-
tions. The potentially significant impact of these cumu-
lative low-grade AEs on patients must also be weighed
against the marginal clinical benefit observed with cer-
tain targeted agents in unselected patient populations.
Fojo and Parkinson [77] have suggested that identifica-
tion of patient subsets by use of clinically validated
biomarkers, developed in parallel with new targeted
therapy, may inform more biologically based patient
selection. This approach offers the potential in the fu-
ture of maximizing efficacy, minimizing toxicity and
effects on QoL, and reducing cost.
Proactive management of these toxicities involves
routine monitoring of clinical symptoms, BP, and labo-
ratory parameters, coupled with early intervention. Ac-
tive and early treatment of adverse effects is vital to
maintain treatment and limit the need for dose reduc-
tions, interruptions, or discontinuations. Successful plan-
ning to anticipate the occurrence of toxicities and
effective management will help ensure that patients with
RCC receiving targeted therapies such as axitinib have
optimal outcomes with AEs that are infrequent, low-
grade, and manageable.
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